NCT00174707 - Study of Docetaxel in Breast Cancer Patients | Biotech Hunter

Enrollment

998

Participants

Timeline

Start Date

December 31, 1997

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Breast Neoplasms

Interventions

DRUG

epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile

Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)

DRUG

epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile

Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)

DRUG

epidoxorubicine, docetaxel, cyclophosphamide

Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)

Trial Locations (1)

Sanofi-Aventis Administrative Office, Milan